Salvage nivolumab/ipilimumab effective in RCC patients unresponsive to upfront nivolumabFebruary 21st 2023
Patients with renal cell carcinoma who had progressive disease or stable disease after frontline nivolumab had a substantial treatment-free survival period following salvage immunotherapy with nivolumab plus ipilimumab.
Expert explains latest developments in surgical management of kidney cancerMarch 18th 2022
Gennady Bratslavsky, MD highlighted studies examining (neo)adjuvant immunotherapy in the setting of nephrectomy for locally advanced disease, such as the PROSPER (NCT03055013) and KEYNOTE-564 (NCT03142334) trials.
Continuous enzalutamide boosts PFS when combined with docetaxel in post-progression mCRPCFebruary 18th 2022
The phase 3b PRESIDE trial showed that continuing enzalutamide in combination with docetaxel and prednisolone delayed disease progression in patients with metastatic castration-resistant prostate cancer who progressed on enzalutamide alone.
FDA approves adjuvant nivolumab in bladder cancerAugust 20th 2021
In a news release, Checkmate -274 primary investigator Matthew Galsky, MD, hailed the approval as a “major milestone for patients who have undergone major surgery to remove the bladder or parts of the urinary tract and are in need of additional treatment approaches that can help reduce the risk of their UC returning."